Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS hosts consortium to discuss broadening subcontinent’s food base
2017-03-14

Description: Cactus Tags: Cactus

The Steering Committee of the Collaborative
Consortium for Broadening the Food Base comprises,
from the left: Prof Wijnand Swart (UFS),
Dr Sonja Venter (ARC) and Dr Eric Amonsou (DUT).
Photo: Andrè Grobler

There is huge pressure on the agricultural industry in southern Africa to avert growing food insecurity. One of the ways to address this is to broaden the food base on the subcontinent via crop production. Climate change, urbanisation, population growth, pests and diseases continually hamper efforts to alleviate food insecurity. Furthermore, our dependence on a few staple crops such as maize, wheat, potatoes, and sunflower, serve to exacerbate food insecurity.  

Broadening the food base  
To address broadening the food base in southern Africa, scientists from the University of the Free State (UFS), the Durban University of Technology (DUT) and the Agricultural Research Council (ARC) have formed a Collaborative Consortium for the development of underutilised crops by focusing on certain indigenous and exotic crops. The Consortium met at the UFS this week for two days (6, 7 March 2017) to present and discuss their research results. The Principal Investigator of the Consortium, Prof Wijnand Swart of the Department of Plant Sciences in the Faculty of Natural and Agricultural Sciences, said awareness had risen for the need to rescue and improve the use of orphan crops that were up to now, for the most part, left aside by research, technological development, and marketing systems.  

"Many indigenous southern African
plant grains, vegetables and tubers
have the potential to provide a variety
of diets and broaden the household
food base.”

Traditional crops Generally referred to as alternative, traditional or niche crops, five crops are being targeted by the Consortium, namely, two grain legumes, (Bambara groundnut and cowpea), amaranthus (leaf vegetable), cactus pear or prickly pear and amadumbe (a potato-like tuber). Swart said these five crops would play an important role in addressing the food and agricultural challenges of the future. “Many indigenous southern African plant grains, vegetables and tubers have the potential to provide a variety of diets and broaden the household food base.” The potential of the many so-called underutilised crops lies not only in their hardiness and nutritional value but in their versatility of utilisation. "It may be that they contain nutrients that can be explored to meet the demand for functional foods," said Swart.

Scientific institutions working together
The Collaborative Consortium between the three scientific institutions is conducting multi-disciplinary research to develop crop value chains for the five underutilised crops mentioned above. The UFS and ARC are mainly involved in looking at production technologies for managing crop environments and genetic technologies for crop improvement. The DUT is focusing on innovative products development and market development.  

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept